Immunotherapy of EL4 lymphoma with reovirus |
| |
| Authors: | G Mark Kollmorgen Don C Cox Jerald J Killion John L Cantrell William A Sansing |
| |
| Institution: | (1) Cancer Research Program, Oklahoma Medical Research Foundation, 825 N.E. 13th Street, 73104 Oklahoma City, Oklahoma, USA;(2) Department of Radiological Sciences, University of Oklahoma, Health Sciences Center, 73104 Oklahoma City, Oklahoma, USA;(3) Department of Botany and Microbiology, University of Oklahoma, 73069 Norman, Oklahoma, USA |
| |
| Abstract: | Summary EL4 lymphoma was grown as an ascitic tumor in the peritoneal cavity of C57Bl/6 mice. Animals with different tumor burdens (either 107 or 109 cells) were treated with a single intraperitoneal injection of BCNU using doses from 20–40 mg/kg. Response as measured by mean survival time and percent survival was dependent on tumor burden and dose of drug. The objective of chemotherapy was to increase the mean survival time, but not the percent survival, in order to evaluate the therapeutic effect of reovirus. Mice were given 108, 109, or 1010 Pfu of reovirus at various times with respect to chemotherapy. The number of mice cured after treatment with both BCNU and reovirus was significantly greater compared to mice treated with BCNU only. Mice cured with combination therapy developed tumor-specific immunity as measured by cytotoxic lymphocytes and serum, and resistance to a lethal tumor challenge.
The Abbreviations used are: BCNU: 1,3-bis-(2-chloroethyl)-1-nitrosourea; Saline: 0.9% NaCl solution; MEM: minimal essential medium; Pfu: plaque-forming units; FCS: fetal calf serum; BME: basal eagle's medium; SSC: sodium citrate-sodium chloride |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
